Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological Consequences

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5555-5563

  Tsatsaris, Vassilis ^b,c   Goffin, Frederic ^a,c   Munaut, Carine ^c   Brichant, Jean François ^a   Pignon, Marie Rose ^c   Noel, Agnes ^c   Schaaps, Jean Pierre ^a,c   Cabrol, Dominique ^b   Frankenne, Francis ^c   Foidart, Jean Michel ^a,c  

^a Centre Hospitalier Regional de La Citadelle   (Belgium)

^b Université Paris Descartes   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MATERNAL PLASMA; MEMBRANE TRANSPORT; PATHOPHYSIOLOGY; PLACENTA DEVELOPMENT; PREECLAMPSIA; PRIORITY JOURNAL; TROPHOBLAST;

ADULT; FEMALE; FETAL GROWTH RETARDATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RNA, MESSENGER; SOLUBILITY; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 10744232684     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030528     Document Type: Article

References (48)

1. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, Caritis SN, Thurnau GR, Bottoms SF, Das A, Roberts JM, McNellis D 1998 The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol 178: 562-567
2. Brosens IA 1977 Morphological changes in the utero-placental bed in pregnancy hypertension. Clin Obstet Gynaecol 4:573-593
3. Brosens I, Dixon HG, Robertson WB 1977 Fetal growth retardation and the arteries of the placental bed. Br J Obstet Gynaecol 84:656-663
4. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK 1989 Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161: 1200-1204
5. Redman CW, Sargent IL 2000 Placental debris, oxidative stress and preeclampsia. Placenta 21:597-602
6. Ahmed A, Perkins J 2000 Angiogenesis and intrauterine growth restriction. Baillieres Best Pract Res Clin Obstet Gynaecol 14:981-998
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442
8. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A 1996 Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439
9. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N 1999 VEGF is required for growth and survival in neonatal mice. Development 126:1149-1159
10. Ferrara N, Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
11. Carmeliet P 2000 Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J 2000 Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248
13. Ferrara N 2000 VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 11:617-624
14. Semenza GL 2001 Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 108:39-40
15. Wang GL, Jiang BH, Rue EA, Semenza GL 1995 Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510-5514
16. Semenza GL 2001 HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13:167-171
17. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ 2001 C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54
18. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992
19. Ahmed A, Dunk C, Ahmad S, Khaliq A 2000 Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen - a review. Placenta 21(Suppl A):S16-S24
20. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT 1992 The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991
21. Fong GH, Rossant J, Gertsenstein M, Breitman ML 1995 Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70
22. Shibuya M 2001 Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 33:409-420
23. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N 2000 A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J 19:4064-4073
24. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS 1996 Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 11:1090-1098
25. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, Smith SK 1994 Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 51: 524-530
26. Kendall RL, Thomas KA 1993 Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709
27. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA 2000 Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80:443-454
28. Yamaguchi S, Iwata K, Shibuya M 2002 Soluble Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 291:554-559
29. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS 1998 A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59:1540-1548
30. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG 2001 Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583
31. Benirschke K, Kaufmann P 2000. Classification of villous maldevelopment., p. 437-460. In: Benirschke K, Kaufman P, eds. Pathology of the human placenta. 4th ed. New York: Springer
32. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA 2002 Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 9:147-160
33. Kingdom JC, Kaufmann P 1999 Oxygen and placental vascular development. Adv Exp Med Biol 474:259-275
34. Khaliq A, Dunk C, Jiang J, Shams M, Li XF, Acevedo C, Weich H, Whittle M, Ahmed A 1999 Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest 79:151-170
35. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ 1999 Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 106:1019-1022
36. Vuorela-Vepsalainen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmaki E 1999 Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 14:1346-1351
37. Sharkey AM, Cooper JC, Balmforth JR, McLaren J, Clark DE, Charnock-Jones DS, Morris NH, Smith SK 1996 Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur J Clin Invest 26:1182-1185
38. Lyall F, Greer IA, Boswell F, Fleming R 1997 Suppression of serum vascular endothelial growth factor immunoreactiviry in normal pregnancy and in preeclampsia. Br J Obstet Gynaecol 104:223-228
39. Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB 1997 Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 38:302-306
40. Hefler L, Obermair A, Husslein P, Kainz C, Tempfer C 2000 Vascular endothelial growth factor serum levels in pregnancy and preeclampsia. Acta Obstet Gynecol Scand 79:77-78
41. Baker PN, Krasnow J, Roberts JM, Yeo KT 1995 Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 86:815-821
42. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ 1979 Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299
43. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, Lewalle JM, Li H, Deroanne CF, Lu H, Colige A, Nusgens BV, Frankenne F, Maron A, Yeh P, Perricaudet M, Chang Y, Soria C, Calberg-Bacq CM, Foidart JM, Noel A 2001 Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 61:3450-3457
44. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB 2002 Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 87:4213-4224
45. Jelkmann W 2001 Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47:617-623
46. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658
47. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y 2003 Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88:2348-2351
48. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE 2003 Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716